| aliskiren vs amlodipine | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | no data | | any adverse event | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| aliskiren vs hydrochlorothiazide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | 1.17 [0.65 2.08] | p=1.00 | 0 | 1124 | 1 | Schmieder (vs HCTZ), | | any adverse event | 1.06 [0.83 1.35] | p=1.00 | 0 | 1124 | 1 | Schmieder (vs HCTZ), | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.70 [0.43 1.14] | p=1.00 | 0 | 1124 | 1 | Schmieder (vs HCTZ), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| aliskiren vs losartan | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | 0.76 [0.32 1.79] | p=1.00 | 0 | 306 | 1 | ALLAY, | | any adverse event | 1.10 [0.70 1.72] | p=1.00 | 0 | 306 | 1 | ALLAY, | | All cause death | 0.99 [0.02 50.07] | p=1.00 | 0 | 306 | 1 | ALLAY, | | Adverse events leading to treatment discontinuation | 0.39 [0.12 1.29] | p=1.00 | 0 | 306 | 1 | ALLAY, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| aliskiren vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | 0.95 [0.55 1.66] | p=1.00 | 0 | 599 | 1 | AVOID, | | any adverse event | 0.99 [0.71 1.40] | p=1.00 | 0 | 599 | 1 | AVOID, | | All cause death | 0.20 [0.01 4.14] | p=1.00 | 0 | 599 | 1 | AVOID, | | Adverse events leading to treatment discontinuation | 0.89 [0.45 1.74] | p=1.00 | 0 | 599 | 1 | AVOID, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| aliskiren vs ramipril | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | no data | | any adverse event | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 4 trials - Schmieder (vs HCTZ) - AVOID - ALLAY - Andersen
| aliskiren vs hydrochlorothiazide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | 1.17 [0.65 2.08] | p=1.00 | 0 | 1124 | 1 | Schmieder (vs HCTZ), | | any adverse event | 1.06 [0.83 1.35] | p=1.00 | 0 | 1124 | 1 | Schmieder (vs HCTZ), | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.70 [0.43 1.14] | p=1.00 | 0 | 1124 | 1 | Schmieder (vs HCTZ), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| aliskiren vs losartan | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | 0.76 [0.32 1.79] | p=1.00 | 0 | 306 | 1 | ALLAY, | | any adverse event | 1.10 [0.70 1.72] | p=1.00 | 0 | 306 | 1 | ALLAY, | | All cause death | 0.99 [0.02 50.07] | p=1.00 | 0 | 306 | 1 | ALLAY, | | Adverse events leading to treatment discontinuation | 0.39 [0.12 1.29] | p=1.00 | 0 | 306 | 1 | ALLAY, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| aliskiren vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | 0.95 [0.55 1.66] | p=1.00 | 0 | 599 | 1 | AVOID, | | any adverse event | 0.99 [0.71 1.40] | p=1.00 | 0 | 599 | 1 | AVOID, | | All cause death | 0.20 [0.01 4.14] | p=1.00 | 0 | 599 | 1 | AVOID, | | Adverse events leading to treatment discontinuation | 0.89 [0.45 1.74] | p=1.00 | 0 | 599 | 1 | AVOID, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| aliskiren vs ramipril | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | no data | | any adverse event | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Diabetic patients : 1 trials - AVOID
| aliskiren vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | 0.95 [0.55 1.66] | p=1.00 | 0 | 599 | 1 | AVOID, | | any adverse event | 0.99 [0.71 1.40] | p=1.00 | 0 | 599 | 1 | AVOID, | | All cause death | 0.20 [0.01 4.14] | p=1.00 | 0 | 599 | 1 | AVOID, | | Adverse events leading to treatment discontinuation | 0.89 [0.45 1.74] | p=1.00 | 0 | 599 | 1 | AVOID, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Nephropathy: 1 trials - AVOID
| aliskiren vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | 0.95 [0.55 1.66] | p=1.00 | 0 | 599 | 1 | AVOID, | | any adverse event | 0.99 [0.71 1.40] | p=1.00 | 0 | 599 | 1 | AVOID, | | All cause death | 0.20 [0.01 4.14] | p=1.00 | 0 | 599 | 1 | AVOID, | | Adverse events leading to treatment discontinuation | 0.89 [0.45 1.74] | p=1.00 | 0 | 599 | 1 | AVOID, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with additional risk factor: 1 trials - ALLAY
| aliskiren vs losartan | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | 0.76 [0.32 1.79] | p=1.00 | 0 | 306 | 1 | ALLAY, | | any adverse event | 1.10 [0.70 1.72] | p=1.00 | 0 | 306 | 1 | ALLAY, | | All cause death | 0.99 [0.02 50.07] | p=1.00 | 0 | 306 | 1 | ALLAY, | | Adverse events leading to treatment discontinuation | 0.39 [0.12 1.29] | p=1.00 | 0 | 306 | 1 | ALLAY, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Uncomplicated hypertension: 3 trials - Schmieder (vs HCTZ) - Andersen - ACCELERATE
| aliskiren vs amlodipine | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | no data | | any adverse event | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| aliskiren vs hydrochlorothiazide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | 1.17 [0.65 2.08] | p=1.00 | 0 | 1124 | 1 | Schmieder (vs HCTZ), | | any adverse event | 1.06 [0.83 1.35] | p=1.00 | 0 | 1124 | 1 | Schmieder (vs HCTZ), | | All cause death | no data | | Adverse events leading to treatment discontinuation | 0.70 [0.43 1.14] | p=1.00 | 0 | 1124 | 1 | Schmieder (vs HCTZ), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| aliskiren vs ramipril | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Serious adverse event | no data | | any adverse event | no data | | All cause death | no data | | Adverse events leading to treatment discontinuation | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
